Diabetes Metab J.  2023 Jul;47(4):484-486. 10.4093/dmj.2023.0165.

The Beneficial Effect of Glycemic Control against Adverse Outcomes in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

• Lee DH

• KMID: 2544727
• DOI: http://doi.org/10.4093/dmj.2023.0165

Reference

1. Kim KS, Park SW, Cho YW, Kim SK. Higher prevalence and progression rate of chronic kidney disease in elderly patients with type 2 diabetes mellitus. Diabetes Metab J. 2018; 42:224–32.

2. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011; 305:2532–9.

3. Johansen KL, Chertow GM, Foley RN, Gilbertson DT, Herzog CA, Ishani A, et al. US Renal Data System 2020 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2021; 77(4 Suppl 1):A7–8.

4. Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol. 2014; 3:99–104.

5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837–53.

6. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560–72.

7. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545–59.

8. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360:129–39.

9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577–89.

10. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic targets: standards of care in diabetes-2023. Diabetes Care. 2023; 46(Suppl 1):S97–110.

11. Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4:1121–7.

12. Navaneethan SD, Zoungas S, Caramori ML, Chan JC, Heerspink HJ, Hurst C, et al. Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO clinical practice Guideline. Ann Intern Med. 2021; 174:385–94.

13. Heo GY, Koh HB, Kim HW, Park JT, Yoo TH, Kang SW, et al. Glycemic control and adverse clinical outcomes in patients with chronic kidney disease and type 2 diabetes mellitus: results from KNOW-CKD. Diabetes Metab J. 2023; 47:484–6.

14. Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011; 171:1920–7.

15. Liao LN, Li CI, Liu CS, Huang CC, Lin WY, Chiang JH, et al. Extreme levels of HbA1c increase incident ESRD risk in Chinese patients with type 2 diabetes: competing risk analysis in national cohort of Taiwan Diabetes Study. PLoS One. 2015; 10:e0130828.

16. Oh SW, Kim YC, Koo HS, Jin DC, Na KY, Chae DW, et al. Glycated haemoglobin and the incidence of end-stage renal disease in diabetics. Nephrol Dial Transplant. 2011; 26:2238–44.